The neuropathology of schizophrenia

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 11, 1996, Pages 72-83

  Bachus, Susan E ^a   Kleinman, Joel E ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYGDALOID NUCLEUS; CINGULATE GYRUS; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ENTORHINAL CORTEX; HIPPOCAMPUS; HUMAN; NEUROPATHOLOGY; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANTIPSYCHOTIC AGENTS; BRAIN; CEREBRAL CORTEX; DOPAMINE; GLUTAMATES; GYRUS CINGULI; HUMANS; LIMBIC SYSTEM; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA;

EID: 0029860751     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (240)

1. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxylyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 1960;38:1236-1239
2. Cotzias GC, VanWoert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379
3. MacLean PD. Contrasting functions of limbic and neocortical systems of the brain and their relevance to psychophysiological aspects of medicine. Am J Med 1958;25:611-626
4. Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry 1973;29:177-189
5. Torrey EF, Peterson MR. Schizophrenia and the limbic system. Lancet 1974;ii:942-946
6. Papez JW. A proposed mechanism of emotion. Archives of Neurology and Psychiatry 1937;38:725-743
7. Nauta WJH. The problem of the frontal lobe: a reinterpretation. J Psychiatr Res 1971;8:167-187
8. Heimer L, Wilson RD. The subcortical projections of the allocortex: similarities in the neural associations of the hippocampus, the piriform cortex, and the neocortex. In: Santini M, ed. Golgi Centennial Symposium. Proceedings. Perspectives in Neurobiology. New York, NY: Raven Press; 1975:177-193
9. Fisman M. The brain stem in psychosis. Br J Psychiatry 1975;126:414-422
10. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry 1990;47:1023-1028
11. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483
12. Seeman P, Lee T, Chau-Wong M, et al. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719
13. DeKeyser J, Claeys A, DeBacker J-P, et al. Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 1988;91:142-147
14. 3H-spiperone binding in normal and schizophrenic post-mortem human brain. Life Sci 1978;23:527-532
15. 3H-apomorphine in schizophrenic brains. Nature 1978;274:897-900
16. Crow TJ, Johnstone EC, Longden AJ, et al. Dopaminergic mechanisms in schizophrenia: the antipsychotic effect and the disease process. Life Sci 1978;23:563-568
17. Owen F, Crow TJ, Poulter M, et al. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 1978;ii:223-226
18. Lee T, Seeman P. Elevation of brain neuroleptic/dopamine receptors in schizophrenia. Am J Psychiatry 1980;137:191-197
19. Mackay AVP, Bird ED, Spokes EG, et al. Dopamine receptors and schizophrenia: drug effect or illness? Lancet 1980;ii:915-916
20. Reisine TD, Rossor M, Spokes E, et al. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue. Adv Biochem Psychopharmacol 1980;21:443-450
21. Reynolds GP, Reynolds LM, Riederer P, et al. Dopamine receptors and schizophrenia: drug effect or illness. Lancet 1980;ii:1251
22. Reynolds GP, Riederer P, Jellinger K, et al. Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 1981;20: 1319-1320
23. 3H-flupenthixol binding in post-mortem brains of schizophrenics: evidence for a selective increase in dopamine D2 receptors. Psychopharmacology (Berl) 1981;74:122-124
24. Toru M, Nishikawa T, Semba J, et al. Increased dopamine metabolism in the putamen and caudate in schizophrenic patients. Advances in the Biosciences 1982;39:235-240
25. Kleinman JE, Karoum F, Rosenblatt JE, et al. Postmortem neurochemical studies in chronic schizophrenia. In: Usdin E, Hanin I, eds. Biological Markers in Psychiatry and Neurology. New York, NY: Pergamon Press; 1982:67-75
26. Mackay AVP, Iversen LL, Rossor M, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 1982;39: 991-997
27. Cross AJ, Crow TJ, Ferrier IN, et al. Dopamine receptor changes in schizophrenia in relation to the disease process and movement disorder. J Neural Transm Suppl 1983;18:265-272
28. Seeman P, Ulpian C, Bergeron C, et al. Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science 1984;225:728-731
29. 3H]SCH 23390 labeled D1 dopamine receptors are unchanged in schizophrenia and Parkinson's disease. Eur J Pharmacol 1985;114:235-237
30. Mita T, Hanada S, Nishino N, et al. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 1986;21:1407-1414
31. Mjörndal T, Winblad B. Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain. Medical Biology 1986; 64:351-354
32. Reynolds GP, Czudek C, Bzowej N, et al. Dopamine receptor asymmetry in schizophrenia. Lancet 1987;i:979
33. Seeman P, Bzowej N, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology 1987;1:5-15
34. Hess EJ, Bracha HS, Kleinman JE, et al. Dopamine receptor subtype imbalance in schizophrenia. Life Sci 1987;40:1487-1497
35. Joyce JN, Lexow N, Bird E, et al. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and schizophrenia. Synapse 1988;2:546-557
36. Toru M, Watanabe S, Shibuya H, et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr Scand 1988;78:121-137
37. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms. J Neural Transm 1989;75:1-10
38. Toru M, Kuramaji A, Kumashiro S, et al. Dopaminergic and glutamatergic abnormalities in postmortem schizophrenic brain. In: Racagni G, Brunello N, Fukuda T, eds. Biological Psychiatry, vol 1. New York, NY: Excerpta Medica; 1991:501-503
39. 3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology (Berl) 1992;109:410-414
40. Reynolds GP, Mason SL. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994;63:1576-1577
41. Knable MB, Hyde TM, Herman MM, et al. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 1994;36:827-835
42. Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia. Eur J Pharmacol 1995;281:R5-R6
43. 125I]epidepride. Eur J Pharmacol 1995;286:R3-R5
44. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977;196:326-328
45. Bogerts B, Häntsch J, Herzer M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiatry 1983;18:951-969
46. 11C-methylspiperone and PET. J Cereb Blood Flow Metab 1985;5(suppl 1):S191-S192
47. Wong DF, Wagner HN Jr, Pearlson G, et al. Dopamine receptor binding of C-11-3-N-methylspiperone in the caudate in schizophrenia and bipolar disorder: a preliminary report. Psychopharmacol Bull 1985;21: 595-598
48. Crawley JCW, Crow TJ, Johnstone EC, et al. Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 1986;ii:224-225
49. Wong DF, Wagner HN Jr, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-1563
50. Farde L, Wiesel F-A, Hall H, et al. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987;44:671-672
51. Wong DF, Tune L, Pearlson G, et al. Dopamine receptor elevations in drug naive schizophrenia and bipolar affective illness measured by C-11 NMSP PET studies: update and methodological considerations. Clin Neuropharmacol 1990;13(S):85-86
52. 11C]raclopride. Arch Gen Psychiatry 1990;47:213-219
53. 11C]NMSP for the PET-determination of central D2-dopamine receptors. Clin Neuropharmacol 1990;13(S):87-88
54. 76Br]bromospiperone in untreated schizophrenic patients. Am J Psychiatry 1990;147: 44-50
55. 76Br-bromolisuride. Br J Psychiatry 1991;158:346-350
56. 11C-N-methylspiperone. Psychiatry Res 1993;49:219-237
57. Hietala J, Syvälahti E, Vuorio K, et al. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch Gen Psychiatry 1994;51:116-123
58. 123I-IBZM single photon emission computerized tomography study. Br J Psychiatry 1994;164:16-26
59. Seeman P. Brain dopamine receptors in schizophrenia: PET problems [letter]. Arch Gen Psychiatry 1988;45:598-599
60. Wong DF, Gjedde A, Tune L, et al. PET results suggest reduced D2 affinity in psychosis in vivo. Biol Psychiatry 1991;29:705S-706S
61. Seeman P, Guan H-C, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-445
62. Van Tol HHM, Bunzow JR, Guan H-C, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610-614
63. Pilowsky LS, Costa DC, Ell PJ, et al. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992;340:199-202
64. Matsumoto M, Hidaka K, Tada S, et al. Full-length cDNA cloning and distribution of human dopamine D4 receptor. Molecular Brain Research 1995;29:157-162
65. 3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 1995;681:109-116
66. Murray AM, Hyde TM, Knable MB, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 1995;15:2186-2191
67. Schoots O, Seeman P, Guan H-C, et al. Long-term haloperidol elevates dopamine D4 receptors by 2-fold in rats. Eur J Pharmacol 1995;289:67-72
68. 3H]nemonapride. J Neurochem 1995;64:1413-1415
69. Seeman P, Van Tol HHM. Dopamine receptor pharmacology. Trends Pharmacol Sci 1994;15:264-270
70. Strange PG, Vile JM. D4 receptors and schizophrenia. J Neurochem 1995;65:2381-2382
71. Seeman P, Van Tol HHM. Dopamine D4 receptors in schizophrenia? [reply letter] J Neurochem 1996;66:882-883
72. Reynolds GP. Dopamine D4 receptors in schizophrenia? [letter] J Neurochem 1996;66:881-882
73. Meador-Woodruff JH, Damask SP, Wang J, et al. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 1996;15:17-29
74. Kerwin RW, Collier D. The dopamine D4 receptor in schizophrenia: an update. Psychol Med 1996;26:221-227
75. Kennedy JL, Petronis A, Gao J, et al. Genetic studies of DRD4 and clinical response to neuroleptic medications. Am J Hum Genet 1994;55(suppl): A190
76. Shaikh S, Collier D, Kerwin RW, et al. Dopamine D4 receptor subtypes and response to clozapine [letter]. Lancet 1993;341:116
77. Kennedy JL, Sidenberg DG, Van Tol HHM, et al. A HincII RFLP in the human D4 dopamine receptor locus (DRD4). Nucleic Acids Res 1991;19:5801
78. Shaikh S, Collier DH, Sham P, et al. An analysis of clozapine response and polymorphisms of the dopamine D4 receptor gene DRD4 in schizophrenic patients. Am J Med Genet. In press
79. Barr CL, Kennedy JL, Lichter JB, et al. Alleles at the dopamine D4 receptor locus do not contribute to the genetic susceptibility to schizophrenia in a large Swedish kindred. Am J Med Genet 1993;48:218-222
80. Shaikh S, Gill M, Owen M, et al. Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia. Am J Med Genet 1994;54:8-11
81. Macciardi F, Petronis A, Van Tol HHM, et al. Analysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindred. Arch Gen Psychiatry 1994;51:288-293
82. Campion D, d'Amato T, Bastard C, et al. Genetic study of dopamine D1, D2, and D4 receptors in schizophrenia. Psychiatry Res 1994;51:215-230
83. Petronis A, Van Tol HHM, Yang L, et al. Population and linkage disequilibrium analysis of new polymorphisms at the DRD4 locus [abstract]. Am J Hum Genet 1993;53(suppl):1707
84. Murray AM, Ryoo HL, Gurevich E, et al. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci U S A 1994;91:11271-11275
85. Schmauss C, Haroutunian V, Davis KL, et al. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci U S A 1993;90: 8942-8946
86. Gurevich E, Kung M-P, Kung H, et al. Dopamine D3 receptors are elevated in schizophrenia and Alzheimer's (AD) cases. Society for Neuroscience Abstracts 1994;20:1169
87. Memo M, Kleinman JE, Hanbauer I. Coupling of dopamine D1 recognition sites with adenylate cyclase in nuclei accumbens and caudatus of schizophrenics. Science 1983;221:1304-1307
88. Seeman P, Niznik HB, Guan H-C, et al. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci U S A 1989;86:10156-10160
89. oα immunoreactivities in left temporal cortices from patients with schizophrenia. Brain Res 1993;615:41-49
90. Okada F, Crow TJ, Roberts GW. G-proteins (Gi, Go) in the basal ganglia of control and schizophrenic brain. J Neural Transm Gen Sect 1990;79:227-234
91. Okada F, Crow TJ, Roberts GW. G-proteins (Gi, Go) in the medial temporal lobe in schizophrenia: preliminary report of a neurochemical correlate of structural change. J Neural Transm Gen Sect 1991;84:147-153
92. Okada F, Tokumitsu Y, Takahashi N, et al. Reduced concentrations of the α-subunit of GTP-binding protein Go in schizophrenic brain. J Neural Transm Gen Sect 1994;95:95-104
93. Jaskiw GE, Weinberger DR. Dopamine and schizophrenia - a cortically corrective perspective. Seminars in the Neurosciences 1992;4:179-188
94. Goldberg TE, Gold JM, Braff DL. Neuropsychological functioning and time-linked information processing in schizophrenia. Review of Psychiatry 1991;10:60-78
95. Johnstone EC, Crow TJ, Frith CD, et al. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet 1976;ii:924-926
96. Weinberger DR, Torrey EF, Neophytides AN, et al. Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. Arch Gen Psychiatry 1979;36:935-939
97. Shelton RC, Weinberger DR. X-ray computerized tomography studies in schizophrenia: a review and synthesis. In: Nasrallah HA, Weinberger DR, eds. Handbook of Schizophrenia, vol 1: The Neurology of Schizophrenia. Amsterdam, The Netherlands: Elsevier Science; 1986:207-250
98. Van Horn JD, Berman KF, Weinberger DR. Pathophysiology of schizophrenia: insights from neuroimaging. In: Watson SJ, ed. Biology of Schizophrenia and Affective Disease. Washington, DC: American Psychiatric Press; 1996:393-419
99. Weinberger DR, DeLisi LE, Perman GP, et al. Computed tomography in schizophreniform disorder and other acute psychiatric disorders. Arch Gen Psychiatry 1982;39:778-783
100. Valk J. Neuroradiological examination of the temporal lobe in chronic psychiatric patients. Radiol Clin Biol 1972;41:422-435
101. DeLisi LE, Dauphinais ID, Gershon ES. Perinatal complications and reduced size of brain limbic structures in familial schizophrenia. Schizophr Bull 1988;14:185-191
102. Suddath RL, Casanova MF, Goldberg TE, et al. Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am J Psychiatry 1989;146:464-472
103. Bogerts B, Meertz E, Schönfeldt-Bausch R. Basal ganglia and limbic system pathology in schizophrenia, a morphometric study of brain volume and shrinkage. Arch Gen Psychiatry 1985;42:784-791
104. Rossi A, Stratta P, D'Albenzio L, et al. Reduced temporal lobe areas in schizophrenia: preliminary evidences from a controlled multiplanar magnetic resonance imaging study. Biol Psychiatry 1990;27:61-68
105. Jernigan TL, Zisook S, Heaton RK, et al. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch Gen Psychiatry 1991;48:881-890
106. Shenton ME, Kikinis R, Jolesz FA, et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia: a quantitative magnetic resonance imaging study. N Engl J Med 1992;327:604-612
107. Stevens JR. Neuropathology of schizophrenia. Arch Gen Psychiatry 1982;39:1131-1139
108. Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol Psychiatry 1984;12:1601-1621
109. Brown R, Colter N, Corsellis JAN, et al. Postmortem evidence of structural brain changes in schizophrenia: differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. Arch Gen Psychiatry 1986;43:36-42
110. Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm 1986;65:303-326
111. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatr Neurol Sci 1986;236:154-161
112. Colter N, Battal S, Crow TJ, et al. White matter reduction in the parahippocampal gyrus of patients with schizophrenia [letter]. Arch Gen Psychiatry 1987;44:1023
113. Altshuler LL, Conrad A, Kovelman JA, et al. Hippocampal pyramidal cell orientation in schizophrenia: a controlled neurohistologic study of the Yakovlev Collection. Arch Gen Psychiatry 1987;44:1094-1098
114. Roberts GW, Colter N, Lofthouse R, et al. Is there gliosis in schizophrenia? investigation of the temporal lobe. Biol Psychiatry 1987;22: 1459-1468
115. Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region - a morphometric study. Biol Psychiatry 1988;24: 515-521
116. Christison GW, Casanova MF, Weinberger DR, et al. A quantitative investigation of hippocampal pyramidal cell size, shape, and variability of orientation in schizophrenia. Arch Gen Psychiatry 1989;46:1027-1032
117. Jeste DV, Lohr JB. Hippocampal pathologic findings in schizophrenia: a morphometric study. Arch Gen Psychiatry 1989;46:1019-1024
118. Altshuler LL, Casanova MF, Goldberg TE, et al. The hippocampus and parahippocampus in schizophrenic, suicide, and control brains. Arch Gen Psychiatry 1990;47:1029-1034
119. Heckers S, Heinsen H, Heinsen Y, et al. Morphometry of the parahippocampal gyms in schizophrenics and controls: some anatomical considerations. J Neural Transm Gen Sect 1990;80:151-155
120. Becker T, Elmer K, Mechela B, et al. MRI findings in medial temporal lobe structures in schizophrenia. Eur Neuropsychopharmacol 1990;1: 83-86
121. Suddath RL, Christison GW, Torrey EF, et al. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322:789-794
122. Casanova M, Saunders R, Altshuler L, et al. Entorhinal cortex pathology in schizophrenia and affective disorders. In: Racagni G, Brunello N, Fukuda T, eds. Biological Psychiatry, vol 1. New York, NY: Excerpta Medica; 1991:504-506
123. Arnold SE, Hyman BT, Van Hoesen GW, et al. Some cytoarchitectural abnormalities of the entorhinal cortex in schizophrenia. Arch Gen Psychiatry 1991;48:625-632
124. Benes FM, Sorensen I, Bird ED. Reduced neuronal size in posterior hippocampus of schizophrenic patients. Schizophr Bull 1991;17:597-608
125. Conrad AJ, Abebe T, Austin R, et al. Hippocampal pyramidal cell disarray in schizophrenia as a bilateral phenomenon. Arch Gen Psychiatry 1991;48:413-417
126. Falkai P, Bogerts B, David S, et al. Postmortem brain morphology in schizophrenia: studies from the new Düsseldorf brain collection. In: Racagni G, Brunello N, Fukuda T, eds. Biological Psychiatry, vol 1. New York, NY: Excerpta Medica; 1991:507-510
127. Breier A, Buchanan RW, Elkashef A, et al. Brain morphology and schizophrenia: a magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992;49:921-926
128. Bogerts B, Lieberman JA, Ashtari M, et al. Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. Biol Psychiatry 1993;33:236-246
129. Marsh L, Suddath RL, Higgins N, et al. Medial temporal lobe structures in schizophrenia: relationship of size to duration of illness. Schizophr Res 1994;11:225-238
130. Jakob H, Beckmann H. Circumscribed malformation and nerve cell alterations in the entorhinal cortex of schizophrenics: pathogenetic and clinical aspects. J Neural Transm Gen Sect 1994;98:83-106
131. Arnold SE, Franz BR, Gur RC, et al. Smaller neuron size in schizophrenia in hippocampal subfields that mediate cortical-hippocampal interactions. Am J Psychiatry 1995;152:738-748
132. Krimer LS, Herman MM, Saunders RC, et al. Qualitative and quantitative analysis of the entorhinal cortex cytoarchitectural organization in schizophrenia. Society for Neuroscience Abstracts 1995;21:239
133. Fukuzako H, Fukuzako T, Hashiguchi T, et al. Reduction in hippocampal formation volume is caused mainly by its shortening in chronic schizophrenia: assessment by MRI. Biol Psychiatry 1996;39:938-945
134. Nestor PG, Shenton ME, McCarley RW, et al. Neuropsychological correlates of MRI temporal lobe abnormalities in schizophrenia. Am J Psychiatry 1993;150:1849-1855
135. Weinberger DR. On the plausibility of "the neurodevelopmental hypothesis" of schizophrenia. Neuropsychopharmacology 1996;14:1S-11S
136. Wolf SS, Hyde TM, Saunders RC, et al. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J Neural Transm Gen Sect 1995;102:55-65
137. Braak H, Braak E. The human entorhinal cortex: normal morphology and lamina-specific pathology in various diseases. Neurosci Res 1992;15: 6-31
138. McGeer PL, McGeer EG. Possible changes in striatal and limbic cholinergic systems in schizophrenia. Arch Gen Psychiatry 1977;34:1319-1323
139. Bird ED, Spokes EG, Barnes J, et al. Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses. Lancet 1977;ii:1157-1159
140. Winblad B, Bucht G, Gottfries CG, et al. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr Scand 1979;60:17-28
141. Crow TJ, Ferrier IN, Johnstone EC, et al. Neuroendocrine aspects of schizophrenia. In: Fink G, Whalley LJ, eds. Neuropeptides: Basic and Clinical Aspects. New York, NY: Churchill Livingstone; 1982:227-238
142. Kerwin R, Robinson P, Stephenson J. Distribution of CCK binding sites in the human hippocampal formation and their alteration in schizophrenia: a postmortem autoradiographic study. Psychol Med 1992;22:37-43
143. Roberts GW, Ferrier IN, Lee Y, et al. Peptides, the limbic lobe and schizophrenia. Brain Res 1983;288:199-211
144. Browning MD, Dudek EM, Rapier JL, et al. Significant reductions in synapsin but not synaptophysin specific activity in the brains of some schizophrenics. Biol Psychiatry 1993;34:529-535
145. Akbarian S, Viñuela A, Kim JJ, et al. Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 1993;50:178-187
146. Barbeau D, Liang JJ, Robitaille Y, et al. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci U S A 1995;92:2785-2789
147. Eastwood SL, Burnet PWJ, Harrison PJ. Altered synaptophysin expression as a marker of synaptic pathology in schizophrenia. Neuroscience 1995;66:309-319
148. 1H MRS) of the hippocampal formation in schizophrenia: a pilot study. Br J Psychiatry 1994;165:484-485
149. Tsai G, Passani LA, Slusher BS, et al. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains. Arch Gen Psychiatry 1995;52:829-836
150. Farmery SM, Owen F, Poulter M, et al. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci 1985;36:473-477
151. Kiuchi Y, Kobayashi T, Takeuchi J, et al. Benzodiazepine receptors increase in post-mortem brain of chronic schizophrenics. Eur Arch Psychiatr Neurol Sci 1989;239:71-78
152. Kerwin R, Patel S, Meldrum B. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 1990;39:25-32
153. Kerwin R. The neurochemical anatomy of the hippocampus in post-mortem schizophrenic brain. Schizophr Res 1990;3:33
154. Joyce JN, Lexow N, Kim SJ, et al. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics. Synapse 1992;10:228-246
155. Joyce JN, Shane A, Lexow N, et al. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 1993;8:315-336
156. Simpson MDC, Slater P, Deakin JFW, et al. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989;107:211-215
157. Reynolds GP, Czukek C, Andrews HB. Deficit and hemispheric asymmetry of GABA uptake sites in the hippocampus in schizophrenia. Biol Psychiatry 1990;27:1038-1044
158. Deakin JFW, Slater P, Simpson MDC, et al. Disturbed brain glutamate and GABA mechanisms in schizophrenia. Schizophr Res 1990;3:33
159. Kerwin RW, Beats BC. Increased forskolin binding in the left parahippocampal gyrus and CA1 region in post mortem schizophrenic brain determined by quantitative autoradiography. Neurosci Lett 1990;118:164-168
160. Collinge J, Curtis D. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Br J Psychiatry 1991;159:857-859
161. Harrison PJ, McLaughlin D, Kerwin RW. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Lancet 1991; 337:450-452
162. Eastwood SL, McDonald B, Burnet PWJ, et al. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Molecular Brain Research 1995;29:211-223
163. Bachus SE, Hyde TM, Shannon Weickert C, et al. Reduced level of excitatory amino acid transporter 3 mRNA in hippocampus of schizophrenics. Society for Neuroscience Abstracts 1996;22:1680
164. Arnold SE, Lee VM-Y, Gur R, et al. Abnormal expression of two microtubule-associated proteins (MAP2 and MAP5) in specific subfields of the hippocampal formation in schizophrenia. Proc Natl Acad Sci U S A 1991;88:10850-10854
165. Akil M, Lewis DA. The catecholaminergic innervation of the human entorhinal cortex: alterations in schizophrenia. Society for Neuroscience Abstracts 1995;21:238
166. Bachus SE, Hyde TM, Herman MM, et al. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. Psychiatry Res. In press
167. Noga JT, Hyde TM, Spurney CF, et al. Glutamate receptor and uptake sites in entorhinal cortex in schizophrenia and controls. American College of Neuropsychopharmacology Abstracts 1994:220
168. Bachus SE, Hyde TM, Herman MM, et al. Elevated AMPA-A mRNA in sulcal entorhinal cortex in schizophrenics and suicides. American College of Neuropsychopharmacology Abstracts 1995:255
169. Royston MC, Slater P, Simpson MDC, et al. Analysis of laminar distribution of kappa opiate receptor in human cortex: comparison between schizophrenia and normal. J Neurosci Methods 1991;36:145-153
170. Gruzelier J, Seymour K, Wilson L, et al. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988;45:623-629
171. Saykin AJ, Shtasel DL, Gur RE, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 1994;51:124-131
172. Friston KJ, Liddle PF, Frith CD, et al. The left medial temporal region and schizophrenia: a PET study. Brain 1992;115:367-382
173. Vogt C, Vogt O. Altérations anatomiques de la schizophrénie et d'autres psychoses dites fonctionelles. In: Proceedings of the 1st International Congress of Neuropathology, vol 1. Torino, Italy: Rosenberg & Sellier; 1952:515-532
174. Palma EC, Sotelo JR. Discussion. In: Proceedings of the 1st International Congress of Neuropathology, vol 1. Torino, Italy: Rosenberg & Sellier; 1952:637-647
175. Braitenberg V. Ricerche istopatologiche sulla corteccia frontale di schizofrenici. In: Proceedings of the 1st International Congress of Neuropathology, vol 1. Torino, Italy: Rosenberg & Sellier; 1952:621-626
176. Colon EJ. Quantitative cytoarchitectonics of the human cerebral cortex in schizophrenic dementia. Acta Neuropathol (Berl) 1972;20:1-10
177. Andreasen N, Nasrallah HA, Dunn V, et al. Structural abnormalities in the frontal system in schizophrenia: a magnetic resonance imaging study. Arch Gen Psychiatry 1986;43:136-144
178. Benes FM, Davidson J, Bird ED. Quantitative cytoarchitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 1986;43: 31-35
179. Benes FM, Majocha R, Bird ED, et al. Increased vertical axon numbers in cingulate cortex of schizophrenics. Arch Gen Psychiatry 1987;44: 1017-1021
180. Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987;44: 608-616
181. Bogerts B, Wurthmann C, Piroth HD. Hirnsubstanzdefizit mit paralimbischem und limbischem Schwerpunkt im CT Schizophrener. Nervenarzt 1987;58:97-106
182. Benes FM, McSparren J, Bird ED, et al. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991;48:996-1001
183. Schlaepfer TE, Harris GJ, Tien AY, et al. Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 1994;151:842-848
184. Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the schizophrenic cortex: a morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 1995;52: 805-818
185. Glantz LA, Lewis DA. Assessment of spine density on layer III pyramidal cells in the prefrontal cortex of schizophrenic subjects. Society for Neuroscience Abstracts 1995;21:239
186. Akbarian S, Kim JJ, Potkin SG, et al. Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients. Arch Gen Psychiatry 1996;53:425-436
187. Benes FM, Sorensen I, Vincent SL, et al. Increased density of glutamate-immunoreactive vertical processes in superficial laminae in cingulate cortex of schizophrenic brain. Cereb Cortex 1992;2:503-512
188. A receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 1992;12:924-929
189. 3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: is selective loss of glulamatergic neurons associated with major psychoses? Neurochem Res 1993;18:219-223
190. Tamminga CA, Thaker GK, Buchanan R, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen
191. Catafau AM, Parellada E, Lomeña FJ, et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 1994;35:935-941
192. Kawasaki Y, Suzuki M, Maeda Y, et al. Regional cerebral blood flow in patients with schizophrenia: a preliminary report. Eur Arch Psychiatry Clin Neurosci 1992;241:195-200
193. Dolan RJ, Fletcher P, Frith CD, et al. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 1995;378:180-182
194. Akbarian S, Bunney WE, Potkin SG, et al. Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 1993;50:169-177
195. Soloway AS, Woo T-U, Lewis DA. Comparison of calbindin- and calretinin-immunoreactive local circuit neurons in the prefrontal cortex of schizophrenic and control subjects. Society for Neuroscience Abstracts 1995;21:239
196. Akbarian S, Kim JJ, Potkin SG, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-266
197. Bennett JP, Enna SJ, Bylund DB, et al. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 1979;36: 927-934
198. 2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect 1991;85: 19-29
199. 2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology. In press
200. Watanabe S, Nishikawa T, Takashima M, et al. Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics. Life Sci 1983;33:2187-2196
201. 3H]kainic acid binding in the prefrontal cortex in schizophrenia. Neurosci Lett 1983;40:245-250
202. 3H]Muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci 1987;40:259-266
203. Fey ET. The performance of young schizophrenics and young normals on the Wisconsin Card Sorting Test. J Consult Psychol 1951;15:311-319
204. Kemali D, Maj M, Galderisi S, et al. Conditional associative learning in drug-free schizophrenic patients. Neuropsychobiology 1987;17:30-34
205. Goldberg TE, Weinberger DR, Pliskin NH, et al. Recall memory deficit in schizophrenia: a possible manifestation of prefrontal dysfunction. Schizophr Res 1989;2:251-257
206. Allen HA, Frith CD. Selective retrieval and free emission of category exemplars in schizophrenia. Br J Psychol 1983;74:481-490
207. Mitchie PT, Fox AM, Ward PB, et al. Event-related potential indices of selective attention and cortical lateralization in schizophrenia. Psychophysiology 1990;27:209-227
208. Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992;49:975-982
209. Seidman LJ, Yurgelun-Todd D, Kremen WS, et al. Relationship of prefrontal and temporal lobe MRI measures to neuropsychological performance in chronic schizophrenia. Biol Psychiatry 1994;35:235-246
210. Weinberger DR, Berman KF, Zec RF. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry 1986;43:114-124
211. Ebert D, Feistel H, Barocka A, et al. A test-retest study of cerebral blood flow during somatosensory stimulation in depressed patients with schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 1993;242:250-254
212. Nakashima Y, Momose T, Sano I, et al. Cortical control of saccade in normal and schizophrenic subjects: a PET study using a task-evoked rCBF paradigm. Schizophr Res 1994;12:259-264
213. Dolan RJ, Bench CJ, Liddle PF, et al. Dorsolateral prefrontal cortex dysfunction in the major psychoses: symptom or disease specificity? J Neurol Neurosurg Psychiatry 1993;56:1290-1294
214. Wolkin A, Sanfilipo M, Wolf AP, et al. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992;49: 959-965
215. Weinberger DR. Anteromedial temporal-prefrontal connectivity: a functional neuroanatomical system implicated in schizophrenia. In: Carroll BJ, Barrett JE, eds. Psychopathology and the Brain. New York, NY: Raven Press; 1991:25-43
216. O'Donnell P, Grace AA. Synaptic interactions among excitatory afferents to nucleus accumbens neurons: hippocampal gating of prefrontal cortical input. J Neurosci 1995;15:3622-3639
217. Weinberger DR, Berman KF, Suddath R, et al. Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 1992;149:890-897
218. Jones EG. Neurotransmitters in the cerebral cortex. J Neurosurg 1986; 65:135-153
219. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience 1981;6:399-405
220. Baleydier C, Mauguière F. The duality of the cingulate gyms in the monkey: neuroanatomical study and functional hypothesis. Brain 1980; 103:525-554
221. Sørensen KE, Witter MP. Entorhinal efferents reach the caudato-putamen. Neurosci Lett 1983;35:259-264
222. Goldman-Rakic PS, Selemon LD, Schwartz ML. Dual pathways connecting the dorsolateral prefrontal cortex with the hippocampal formation and parahippocampal cortex in the rhesus monkey. Neuroscience 1984;12: 719-743
223. Selemon LD, Goldman-Rakic PS. Longitudinal topography and interdigitation of corticostriatal projections in the rhesus monkey. J Neurosci 1985;5:776-794
224. Swanson LW, Köhler C. Anatomical evidence for direct projections from the entorhinal area to the entire cortical mantle in the rat. J Neurosci 1986; 6:3010-3023
225. Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey, II: cortical afferents. J Comp Neurol 1987;264:356-395
226. Selemon LD, Goldman-Rakic PS. Common cortical and subcortical targets of the dorsolateral prefrontal and posterior parietal cortices in the rhesus monkey: evidence for a distributed neural network subserving spatially guided behavior. J Neurosci 1988;8:4049-4068
227. Newman R, Winans SS. An experimental study of the ventral striatum of the golden hamster, II: neuronal connections of the olfactory tubercle. J Comp Neurol 1980;191:193-212
228. Deutsch SI, Mastropaolo J, Schwartz BL, et al. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989;12:1-13
229. Sherman AD, Davidson AT, Baruah S, et al. Evidence of glutamatergic deficiency in schizophrenia. Neurosci Lett 1991;121:77-80
230. Sherman AD, Hegwood TS, Baruah S, et al. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol Psychiatry 1991;30:1191-1198
231. Simpson MDC, Royston MC, Slater P, et al. Phencyclidine and sigma receptor abnormalities in schizophrenic post mortem brain. Schizophr Res 1990;3:32
232. Ishimaru M, Kurumaji A, Toru M. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenics: evidence for glutamate hypothesis. Biol Psychiatry 1994;35:84-95
233. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996;16:19-30
234. Simpson MDC, Slater P, Royston MC, et al. Regionally selective deficits in uptake sites for glutamate and gamma-aminobutyric acid in the basal ganglia in schizophrenia. Psychiatry Res 1992;42:273-282
235. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 1989;77:231-236
236. Yang CR, Mogenson GJ. Electrophysiological responses of neurones in the nucleus accumbens to hippocampal stimulation and the attenuation of the excitatory responses by the mesolimbic dopaminergic system. Brain Res 1984;324:69-84
237. Riederer P, Lange KW, Kornhuber J, et al. Glutamatergic-dopaminergic balance in the brain: its importance in motor disorders and schizophrenia. Arzneimittelforschung 1992;42:265-268
238. Montgomery SA, Green MCD. The use of cholecystokinin in schizophrenia: a review. Psychol Med 1988;18:593-603
239. 11C]N-methylspiperone. Psychiatry Res Neuroimaging 1995;61:67-83
240. Deakin JFW, Slater P, Simpson MDC, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52:1781-1786